Received Apr 27, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 79MR9 | — |
the patient received the 1st dose on 14-JUN-2022 and received second dose on 17-APR-2026; they reconstituted the vaccine with sterile water; they reconstituted the vaccine with sterile water; This non-serious case was reported by a physician via call center representative and described the occurrence of drug dose administration interval too long in a 58-year-old male patient who received Herpes zoster (Shingrix) (batch number 79MR9) for prophylaxis. Previously administered products included Shingrix (received first dose on 14-JUN-2022). On 17-APR-2026, the patient received the 2nd dose of Shingrix. On 17-APR-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: the patient received the 1st dose on 14-JUN-2022 and received second dose on 17-APR-2026), inappropriate preparation of medication (Verbatim: they reconstituted the vaccine with sterile water) and inappropriate dose of vaccine administered (Verbatim: they reconstituted the vaccine with sterile water). The outcome of the drug dose administration interval too long, inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date:17-APR-2026 The Vaccine Administration Facility was the same as Primary Reporter.